Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+HER2-metastatic breast cancer

被引：2

作者：

Marme, F. ^{[1
]}

Wildiers, H. ^{[2
,3
]}

Dirix, L. ^{[4
]}

Armstrong, A. ^{[5
]}

De Cuypere, E. ^{[6
]}

Dalenc, F. ^{[7
]}

Schroder, C. Pia ^{[8
]}

Vuylsteke, P. ^{[9
]}

Brain, E. ^{[10
]}

Kuemmel, S. ^{[11
,12
]}

Papai, Z. ^{[13
]}

Mueller, C. ^{[14
]}

Brignone, C. ^{[15
]}

Triebel, F. ^{[15
]}

机构：

[1] Heidelberg Univ, Univ Hosp Mannheim, Fac Med, Mannheim, Germany

[2] Dept Gen Med Oncol, Oncol, Leuven, Belgium

[3] Multidisciplinary Breast Ctr, Leuven, Belgium

[4] 3 GZA Ziekenhuizen, Oncol, Campus Sint Augustinus, Antwerp, Belgium

[5] Christie NHS Fdn Trust, Oncol, Manchester, Lancs, England

[6] Brugge Oostende AV, AZ Sint Jan 5, Oncol, Brugge, Belgium

[7] Inst Claudius Regaud, Oncol, Toulouse, France

[8] Univ Med Ctr Groningen, Oncol, Groningen, Netherlands

[9] Clin St Elizabeth, Oncol, Uccle, Belgium

[10] Hop Rene Huguenin, Inst Curie 12, Oncol, St Cloud, France

[11] KEM, Breast Unit, Essen, Germany

[12] Evang Kliniken Essen Mitte, Essen, Germany

[13] 13 MH Egeszsegugyi Kozpont Onkol Osztaly, Oncol, Budapest, Hungary

[14] Immutep GmbH, Clin & Regulatory, Berlin, Germany

[15] Immutep SAS, Res & Dev, Orsay, France

来源：

关键词：

D O I：

10.1016/j.annonc.2022.03.190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

171P

引用

页码：S203 / S204

页数：2